AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34794118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fun For Wellness intervention
Number of subjects: 461
Study 34794172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 2310
Study 34794172 — intervention group
Group type: COMPARATOR
Intervention: Hypomethylating agents
Number of subjects: 2310
Study 34794172 — intervention group
Group type: COMPARATOR
Intervention: sAML
Number of subjects: 2310
Study 34794172 — intervention group
Group type: COMPARATOR
Intervention: sAML after hematologic disorder
Number of subjects: 2310
Study 34794387 — intervention group
Group type: EXPERIMENTAL
Intervention: OR extubation group
Number of subjects: 438
Study 34794387 — intervention group
Group type: COMPARATOR
Intervention: ICU extubation group
Number of subjects: 438
Study 34794396 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with liposomal irinotecan (nal-IRI), oxaliplatin (OX), and 5-fluouracil/folinic acid (FA) (NAPOX)
Number of subjects: 150
Study 34794412 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab-containing arms
Number of subjects: 5
Study 34794412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 5
Study 34794412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib + Olaparib
Number of subjects: 5
Study 34794412 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 5
Study 34794412 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Olaparib
Number of subjects: 5
Study 34794420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) starting dosage 30 mg/kg/day in 6 hours
Number of subjects: 30
Study 34794420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30
Study 34794514 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 0
Study 34794682 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth extraction in kidney transplant recipients
Number of subjects: 95
Study 34794682 — intervention group
Group type: COMPARATOR
Intervention: Tooth extraction in control patients (non-kidney transplant)
Number of subjects: 95
Study 34794687 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month DAPT
Number of subjects: 3652
Study 34794687 — intervention group
Group type: COMPARATOR
Intervention: 3-month DAPT
Number of subjects: 3652
Study 34794987 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 40
Study 34794987 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 40
Study 34794987 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 40
Study 34794989 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy with androgen deprivation therapy (ADT) and intensification with agents such as docetaxel, abiraterone acetate, and enzalutamide.
Number of subjects: 300
Study 34794989 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cytoreductive approaches (external beam radiotherapy, cytoreductive radical prostatectomy, or minimally invasive ablative therapy) and metastases-directed therapies (metastasectomy or stereotactic ablative body radiotherapy).
Number of subjects: 300
Study 34794989 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis component with patients (n=15) and healthcare professionals (n=5).
Number of subjects: 300
Study 34795005 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI camrelizumab plus gemcitabine and oxaliplatin
Number of subjects: 98
Study 34795005 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic signature including 11 genes
Number of subjects: 98
Study 34795005 — intervention group
Group type: EXPERIMENTAL
Intervention: High mutation load in KRAS signaling genes
Number of subjects: 98
Study 34795005 — intervention group
Group type: EXPERIMENTAL
Intervention: Signature wild-type subtype with favorable TME
Number of subjects: 98
Study 34795065 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 1894
Study 34795065 — intervention group
Group type: COMPARATOR
Intervention: secukinumab 150 mg
Number of subjects: 1894
Study 34795131 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute infusion of ramucirumab
Number of subjects: 559
Study 34795131 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute infusion of ramucirumab
Number of subjects: 559
Study 34795254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PD-1 blockade)
Number of subjects: 14
Study 34795408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib (60 mg BID, RP2D; 80 mg BID, MTD)
Number of subjects: 101
Study 34795408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib in epithelial ovarian cancer (EOC) population (n=51)
Number of subjects: 101
Study 34795408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib (80 mg BID)
Number of subjects: 101
Study 34795408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib (dose-escalation phase)
Number of subjects: 101
Study 34795409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic PET/computed tomography imaging
Number of subjects: 39
Study 34795626 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 34795635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap Test intervention, details not specified
Number of subjects: 0
Study 34795635 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34795912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pemetrexed-cisplatin chemoradiotherapy
Number of subjects: 0
Study 34795912 — intervention group
Group type: COMPARATOR
Intervention: Etoposide-cisplatin chemoradiotherapy
Number of subjects: 0
Study 34796337 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cabozantinib and nivolumab
Number of subjects: 15
Study 34796373 — intervention group
Group type: EXPERIMENTAL
Intervention: Y90 glass microspheres (TheraSphere™)
Number of subjects: 115
Study 34796395 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 225
Study 34796395 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (per 1 year)
Number of subjects: 225
Study 34796395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower maternal educational level (≥ high school vs. < high school)
Number of subjects: 225
Study 34796395 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased parent and self-identification of medication barriers (per 1 point)
Number of subjects: 225
Study 34796395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence
Number of subjects: 225
Study 34796678 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase
Number of subjects: 1711
Study 34796678 — intervention group
Group type: EXPERIMENTAL
Intervention: L2-L3 VAT
Number of subjects: 1711
Study 34796678 — intervention group
Group type: EXPERIMENTAL
Intervention: L3-L4 VAT
Number of subjects: 1711
Study 34796678 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin concentration
Number of subjects: 1711
Study 34796678 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin concentration
Number of subjects: 1711
Study 34796742 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 4791
Study 34796742 — intervention group
Group type: COMPARATOR
Intervention: Patients without COPD
Number of subjects: 4791
Study 34796742 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome
Number of subjects: 4791
Study 34797012 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter-defibrillator (S-ICD)
Number of subjects: 176
Study 34797012 — intervention group
Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 176
Study 34797221 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin administered at 3 mL/kg by intravenous infusion over 30 minutes
Number of subjects: 15
Study 34797221 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 15
Study 34797221 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine for hemodynamic support
Number of subjects: 15
Study 34797307 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test in FM patients
Number of subjects: 40
Study 34797307 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 34797405 — intervention group
Group type: COMPARATOR
Intervention: MRI findings classified as severe (Schizas C+D)
Number of subjects: 437
Study 34797405 — intervention group
Group type: COMPARATOR
Intervention: MRI findings (cross-sectional area < 75 mm²)
Number of subjects: 437
Study 34797405 — intervention group
Group type: COMPARATOR
Intervention: Preoperative scores for Oswestry Disability Index, Zurich Claudication Questionnaire, and Numeric rating scale for back and leg pain
Number of subjects: 437
Study 34797699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib with Rituximab (IR)
Number of subjects: 50
Study 34797725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 0
Study 34797725 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 0
Study 34797737 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Number of subjects: 0
Study 34797737 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-6 Fatty Acids
Number of subjects: 0
Study 34797737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34797911 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic interleukin-15 (IL-15; N-803)
Number of subjects: 0
Study 34797911 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-15/N-803
Number of subjects: 0
Study 34797911 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-15
Number of subjects: 0
Study 34797955 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mentor mothers (cMMs) intervention with ≥4 home visits up to 6 weeks postpartum
Number of subjects: 589
Study 34797955 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mentor mothers (cMMs) intervention
Number of subjects: 589
Study 34798051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade mosaic embryos
Number of subjects: 484
Study 34798051 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-grade mosaic embryos
Number of subjects: 484
Study 34798051 — intervention group
Group type: COMPARATOR
Intervention: Euploid embryos
Number of subjects: 484
Study 34798080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative heart rate characteristics (HRC) index
Number of subjects: 598
Study 34798080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative mean HRC score included in predictive models
Number of subjects: 598
Study 34798080 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsimonious model including birth weight, sex, ventilatory status, and cumulative mean HRC score
Number of subjects: 598
Study 34798334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 1000
Study 34798899 — intervention group
Group type: EXPERIMENTAL
Intervention: Four random cervical biopsies
Number of subjects: 173
Study 34798899 — intervention group
Group type: COMPARATOR
Intervention: One cervical biopsy
Number of subjects: 173
Study 34799295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic computed tomography perfusion (CTP) with regadenoson prior to and at least 3 months after successful CTO recanalization
Number of subjects: 10
Study 34799399 — intervention group
Group type: EXPERIMENTAL
Intervention: NIZ985 (0.25, 0.5, 1, 2 or 4 µg/kg subcutaneous TIW for the first 2 weeks of each 28-day cycle)
Number of subjects: 14
Study 34799399 — intervention group
Group type: EXPERIMENTAL
Intervention: NIZ985
Number of subjects: 14
Study 34799400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 937
Study 34799400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 937
Study 34799400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 937
Study 34799430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 701
Study 34799430 — intervention group
Group type: COMPARATOR
Intervention: Usual obesity care
Number of subjects: 701
Study 34799430 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes remission at 10-year follow-up
Number of subjects: 701
Study 34799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical and nonsurgical procedures under anaesthesia
Number of subjects: 9497
Study 34799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned ICU admission
Number of subjects: 9497
Study 34799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned ICU admission
Number of subjects: 9497
Study 34799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to a unit with geriatric care within 30 days after the intervention
Number of subjects: 9497
Study 34799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 9497
Study 34799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 9497
Study 34799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited mobility
Number of subjects: 9497
Study 34799745 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral incisionless fundoplication (TIF) with Medigus Ultrasonic Surgical Endostapler (MUSE)
Number of subjects: 46
Study 34800109 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab in combination with pomalidomide plus dexamethasone
Number of subjects: 0
Study 34800167 — intervention group
Group type: EXPERIMENTAL
Intervention: Myasthenia gravis patients (MG)
Number of subjects: 1660
Study 34800167 — intervention group
Group type: COMPARATOR
Intervention: General population (genP)
Number of subjects: 1660
Study 34800279 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for cardioembolic LVO (CE-LVO)
Number of subjects: 1635
Study 34800279 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) for other stroke subtypes
Number of subjects: 1635
Study 34800283 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 1321
Study 34800495 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy (FBMT)
Number of subjects: 9
Study 34800495 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine consumption
Number of subjects: 9
Study 34800678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibostolimab monotherapy (2.1-700 mg)
Number of subjects: 76
Study 34800678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibostolimab plus pembrolizumab (200 mg) combination therapy
Number of subjects: 76
Study 34800678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibostolimab plus pembrolizumab combination therapy in anti-PD-1/PD-L1-naive NSCLC
Number of subjects: 76
Study 34800678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibostolimab monotherapy in anti-PD-1/PD-L1-refractory NSCLC
Number of subjects: 76
Study 34800678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibostolimab plus pembrolizumab combination therapy in anti-PD-1/PD-L1-refractory NSCLC
Number of subjects: 76
Study 34800701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab alone or in combination with ipilimumab
Number of subjects: 44
Study 34800988 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative physical therapy
Number of subjects: 157
Study 34800988 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: Pain levels during hospitalization
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: Size of tumors
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: Breast reconstructions
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: More than three dissected lymph nodes
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: Presence of preoperative pain
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: In-hospital pain
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: Axillary web syndrome
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: Lymphedema
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: Radiation
Number of subjects: 157
Study 34800988 — intervention group
Group type: COMPARATOR
Intervention: Size of dissected tissue
Number of subjects: 157
Study 34801015 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 737
Study 34801015 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (calcium and active vitamin D)
Number of subjects: 737
Study 34801051 — intervention group
Group type: EXPERIMENTAL
Intervention: Weifuchun (WFC) tablets, 1.44 g three times a day for 6 months
Number of subjects: 0
Study 34801051 — intervention group
Group type: COMPARATOR
Intervention: Vitacoenzyme (Vit) tablets, 0.8 g three times a day for 6 months
Number of subjects: 0
Study 34801051 — intervention group
Group type: EXPERIMENTAL
Intervention: WFC treatment
Number of subjects: 0
Study 34801051 — intervention group
Group type: COMPARATOR
Intervention: Parabacteroides
Number of subjects: 0
Study 34801354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL2a)
Number of subjects: 42
Study 34801354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 2 mg QD (intermittent DL2)
Number of subjects: 42
Study 34801354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL1)
Number of subjects: 42
Study 34801354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 1.5 mg QD (concurrent DL2b)
Number of subjects: 42
Study 34801354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W plus trametinib 2 mg QD (intermittent DL1)
Number of subjects: 42
Study 34801462 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 71
Study 34801581 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i)
Number of subjects: 77
Study 34801581 — intervention group
Group type: COMPARATOR
Intervention: Control (non-diabetic recipients)
Number of subjects: 77
Study 34801581 — intervention group
Group type: COMPARATOR
Intervention: Diabetic recipients without SGLT2i
Number of subjects: 77
Study 34801592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum biomarkers (sialic acid, hypoxanthine, xanthine, methylthioadenosine, adenine, glutathione)
Number of subjects: 980
Study 34801735 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG patch monitoring pre-, immediately post-, and 2-3 months post-TAVR
Number of subjects: 96
Study 34801735 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG patch monitoring
Number of subjects: 96
Study 34801749 — intervention group
Group type: EXPERIMENTAL
Intervention: Aumolertinib (110 mg orally once daily)
Number of subjects: 244
Study 34802036 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 479
Study 34802344 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related present bias (PB)
Number of subjects: 0
Study 34802428 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation exercises as a teaching method
Number of subjects: 6
Study 34802428 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating a safe environment, facilitating student-centred learning, and promoting reflection
Number of subjects: 6
Study 34802427 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible and integrated treatment (FIT) model project at the model hospital
Number of subjects: 600
Study 34802427 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes in the model hospital
Number of subjects: 600
Study 34802427 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 600
Study 34802455 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated uniform with 30% DEET liposome formula
Number of subjects: 0
Study 34802455 — intervention group
Group type: COMPARATOR
Intervention: Permethrin-treated uniform with placebo lotion
Number of subjects: 0
Study 34802455 — intervention group
Group type: EXPERIMENTAL
Intervention: Etofenprox-treated uniform with 30% DEET liposome formula
Number of subjects: 0
Study 34802455 — intervention group
Group type: COMPARATOR
Intervention: Untreated uniforms with placebo lotion
Number of subjects: 0
Study 34802467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberry/red grape juice
Number of subjects: 60
Study 34802467 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 60
Study 34802696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane general anaesthesia
Number of subjects: 72
Study 34802792 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (first dose)
Number of subjects: 96
Study 34802792 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine (second dose)
Number of subjects: 96
Study 34802864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg and docetaxel 75 mg/m²
Number of subjects: 84
Study 34802864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus docetaxel
Number of subjects: 84
Study 34802966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg initiated, average dose 45.5 mg/day)
Number of subjects: 100
Study 34802966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (treatment line subgroups)
Number of subjects: 100
Study 34802966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (CCI score comparison)
Number of subjects: 100
Study 34803050 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care Intervention plus Cancer Prevention Care Management (CCI+PCM)
Number of subjects: 757
Study 34803050 — intervention group
Group type: COMPARATOR
Intervention: Cancer Prevention Care Management (PCM) alone
Number of subjects: 757
Study 34803301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohydroxyapatite (NHA)
Number of subjects: 72